Figure 3 — Caffeic acid derivative MPMCA suppresses osteoclastogenesis and facilitates osteoclast apoptosis: implications for the treatment of bone loss disorders

Research Paper|Volume 16, Issue 16|pp. 11926–11938

Caffeic acid derivative MPMCA suppresses osteoclastogenesis and facilitates osteoclast apoptosis: implications for the treatment of bone loss disorders

Back to articleFigure 3(3 of 8)

100%

Figure 3.MPMCA inhibits the expression of osteoclast markers. (A) The GEO database (GSE21639) stores data showcasing the expression levels of osteoclast markers throughout the process of differentiating RAW 264.7 cells into osteoclasts by RANKL treatment. (B–D) qRT-PCR was used to assess the mRNA expression of osteoclast markers in RAW 264.7 cells. RAW 264.7 cells were exposed to RANKL and MPMCA for a period of 5 days (n = 3). ^*p < 0.05 vs. control group. ^#p < 0.05 vs. RANKL-treated group.